Abstract
Macrophage Stimulating Protein (MSP) is the only known ligand for the receptor tyrosine kinase Ron. The MSP/Ron pathway is involved in several important biological processes, including macrophage activity, wound healing, and epithelial cell behavior. A role for MSP/Ron in breast cancer has recently been elucidated, wherein this pathway regulates tumor growth, angiogenesis, and metastasis. Here, we review the recent literature surrounding MSP/Ron function in tumor cells, inflammatory cells, and osteoclasts – cell types that often coexist in breast tumor microenvironments. We discuss the potential implications of MSP/Ron activity occurring concurrently in these cell types on tumor progression and metastasis. Lastly, we outline the potential for targeting MSP/Ron as a novel therapy for breast cancer, and for other cancer types.
Keywords: Breast cancer, macrophage stimulating protein, metastasis, MSP, MST1R, osteolysis, Ron, therapeutic target
Current Drug Targets
Title: The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Volume: 11 Issue: 9
Author(s): Kelsi L. Kretschmann, Henok Eyob, Saundra S. Buys and Alana L. Welm
Affiliation:
Keywords: Breast cancer, macrophage stimulating protein, metastasis, MSP, MST1R, osteolysis, Ron, therapeutic target
Abstract: Macrophage Stimulating Protein (MSP) is the only known ligand for the receptor tyrosine kinase Ron. The MSP/Ron pathway is involved in several important biological processes, including macrophage activity, wound healing, and epithelial cell behavior. A role for MSP/Ron in breast cancer has recently been elucidated, wherein this pathway regulates tumor growth, angiogenesis, and metastasis. Here, we review the recent literature surrounding MSP/Ron function in tumor cells, inflammatory cells, and osteoclasts – cell types that often coexist in breast tumor microenvironments. We discuss the potential implications of MSP/Ron activity occurring concurrently in these cell types on tumor progression and metastasis. Lastly, we outline the potential for targeting MSP/Ron as a novel therapy for breast cancer, and for other cancer types.
Export Options
About this article
Cite this article as:
L. Kretschmann Kelsi, Eyob Henok, S. Buys Saundra and L. Welm Alana, The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression, Current Drug Targets 2010; 11 (9) . https://dx.doi.org/10.2174/138945010792006825
DOI https://dx.doi.org/10.2174/138945010792006825 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry Contribution of Magnetic Resonance Imaging in Determining Lumpectomy Cavity in Breast Radiotherapy
Current Medical Imaging Amygdalin Decreases Adhesion and Migration of MDA-MB-231 and MCF-7 Breast Cancer Cell Lines
Current Molecular Pharmacology Treatment of High-Grade Pelvic-Type Serous Carcinomas (Ovary, Fallopian Tube and Peritoneum): Current Therapeutic Paradigms, Prospects, and Challenges
Current Cancer Therapy Reviews Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics
Current Clinical Pharmacology CD147: A Novel Modulator of Inflammatory and Immune Disorders
Current Medicinal Chemistry Heparan Sulphate as a Regulator of Leukocyte Recruitment in Inflammation
Current Protein & Peptide Science Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials
Anti-Cancer Agents in Medicinal Chemistry Regulation of MicroRNAs by Phytochemicals: A Promising Strategy for Cancer Chemoprevention
Current Cancer Drug Targets Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry The Effects of Nanoencapsulated Curcumin-Fe3O4 on Proliferation and hTERT Gene Expression in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Aquaporin Biology and Nervous System
Current Neuropharmacology Radiation-Induced Response of Micro RNA Expression in Murine Embryonic Stem Cells
Medicinal Chemistry A Novel Combined Pharmacophore Mapping and Quantitative Structure Selectivity Relationship Analysis for the Development of Potent and Selective Human Aldose Reductase Inhibitors
Current Computer-Aided Drug Design Xanthan Gum and Its Derivatives as a Potential Bio-polymeric Carrier for Drug Delivery System
Current Drug Delivery Single Nucleotide Polymorphisms in Colitis-Associated Colorectal Cancer: A Current Overview with Emphasis on the Role of the Associated Genes Products
Current Drug Targets